Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by $0.25, Briefing.com reports. During the same quarter last year, the firm posted ($0.62) earnings per share.

Esperion Therapeutics (NASDAQ ESPR) opened at 52.13 on Wednesday. The firm’s market cap is $1.18 billion. The firm’s 50-day moving average price is $45.38 and its 200 day moving average price is $33.91. Esperion Therapeutics has a 52-week low of $9.40 and a 52-week high of $57.38.

ESPR has been the subject of several recent research reports. Zacks Investment Research cut Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. ValuEngine raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Citigroup Inc. reissued a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Deutsche Bank AG started coverage on Esperion Therapeutics in a research report on Friday, June 23rd. They set a “buy” rating and a $48.00 target price on the stock. Finally, BidaskClub raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, June 25th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $39.16.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/esperion-therapeutics-inc-espr-releases-quarterly-earnings-results-misses-estimates-by-0-30-eps.html.

A number of hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $1,498,000. UBS Asset Management Americas Inc. acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $6,608,000. Pictet Asset Management Ltd. acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $4,539,000. Bank of New York Mellon Corp boosted its stake in Esperion Therapeutics by 29.4% in the first quarter. Bank of New York Mellon Corp now owns 104,603 shares of the biopharmaceutical company’s stock valued at $3,693,000 after buying an additional 23,740 shares in the last quarter. Finally, Princeton Alpha Management LP acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $205,000. Hedge funds and other institutional investors own 85.20% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.